Since October 1, 2010, Vectura’s financial performance has exceeded the board’s expectations, according to the company’s interim management statement. Chief Executive Chris Blackwell attributes the improved performance to a restructured R&D program and says that Vectura expects to have more than £73m cash on hand by March 31, 2010. Read the company’s press release.
Vectura announces better than expected financial results
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
